Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
31 hedge funds and large institutions have $14M invested in Landos Biopharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 8 closing their positions.
9% less funds holding
Funds holding: 34 → 31 (-3)
14% less capital invested
Capital invested by funds: $16.4M → $14M (-$2.31M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
+$73.3K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.9K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.6K |
| 4 |
Man Group
London,
United Kingdom
|
+$12.5K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$972 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
OUP Management Company
Bala Cynwyd,
Pennsylvania
|
-$325K |
| 2 |
RI
RTW Investments
New York
|
-$260K |
| 3 |
Renaissance Technologies
New York
|
-$113K |
| 4 |
Goldman Sachs
New York
|
-$25.8K |
| 5 |
Two Sigma Investments
New York
|
-$23.5K |
LABP Hedge Fund Activity: Q3 2022 in Review
31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q3 2022, worth a combined $14M — down 14% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LABP and 5 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 5 added.
The largest buyer was Steel Grove Capital Advisors, opening a new position worth an estimated $73.3K. The largest seller was OUP Management Company, cutting an estimated $325K.
- 31 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q3 2022, down from 34 in Q2 2022.
- Funds reported $14M of Landos Biopharma, Inc. Common Stock stock for Q3 2022, down 14% quarter-over-quarter.
- 5 funds opened new Landos Biopharma, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -3 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q3 2022 was Steel Grove Capital Advisors, an estimated $73.3K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q3 2022 was OUP Management Company, an estimated $325K sold.
Based on aggregated 13F filings for Q3 2022.